Diagnostic & mechanistic studies
tested GH peak concentration
result 0.2 mg/kg induced GH in all 14 subjects (mean peak 41.0 ± 6.3 µg/L); 1.0 mg/kg yielded peak 82.5 ± 14.9 µg/L.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested GH secretion response
result GHRP-6 elicits GH responses greater than those evoked by GHRH in obese patients, though still lower than in lean subjects.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested GH peak concentration and AUC after GHRP-6, GHRH, and combined test
result GH peak after GHRP-6: 50.95±11.55 (normal-weight NIDDM), 51.96±7.71 (overweight NIDDM), 70.07±15.59 mU/L (controls); P>.05
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested GH, ACTH, cortisol, sleep stage 2
result GHRP-6 i.n. increased GH, trended increase in ACTH
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested GH peak and AUC
result Normal men: GHRP-6 peak GH 39.3±7.1 µg/L (AUC 1958.8±445.7) after metyrapone vs 21.9±4.5 µg/L (AUC 1131.0±229.6) with placebo. Patients: peak 11.8±3.9 (AUC 563.2±208.7) on replacement vs 14.4±4.5 (AUC 695.6±272.9) after withdrawal.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested ACTH release (and cortisol) after GHRP-6
result In patients (n=6) ACTH increased from 38.1 ± 17.1 to 174.9 ± 79.4 pmol/L after GHRP-6; controls rose from 2.9 ± 0.8 to 4.7 ± 1.4 pmol/L. After 72 h glucocorticoid withdrawal basal ACTH rose to 191.2 ± 97.3 pmol/L (p=0.053).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested ACTH and cortisol levels (peak and AUC)
result GHRP-6 raised ACTH from 15.5±1.7 to 45.1±9.3 pmol/L and cortisol from 583±90.8 to 1013.4±194.6 nmol/L; DDAVP produced similar increases (ACTH 13.0→50.5, cortisol 572.5→860.5).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested GH peak response
result Obese PCOS women showed a significantly higher GH peak after GHRH+GHRP-6 before fasting; fasting further enhanced GH response in both PCOS and control groups.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested stage 4 sleep, EEG delta power, GH, prolactin, ACTH, cortisol
result Hexarelin (4×50 µg) reduced stage 4 sleep and total‑night EEG delta power, while increasing GH and prolactin throughout the night and ACTH and cortisol in the first half.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested diagnostic accuracy (ROC AUC)
result ROC AUC: GH peak 0.9997; AUC 0.9993; no statistical difference.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested GH, ACTH, cortisol, and glucose secretion
result In CD, GHRP-6 induced GH peak 2.7±1.0 µg/L vs controls 22.9±4.8 µg/L; ACTH response similar to ghrelin (185±56 pg/mL) and higher than controls (23.6±5.7 pg/mL).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested ACTH and cortisol response to GHRP-6
result Patients with an ACTH/cortisol response to GHRP-6 had higher tumor GHSR-1a mRNA expression than non‑responders.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested ACTH and cortisol AUC response to ghrelin and GHRP-6
result Basal cortisol higher in patients (10.7±0.7) vs controls (8.1±0.7); basal ACTH higher (21.5±2.9 vs 13.5±1.8). Ghrelin‑stimulated ACTH AUC markedly higher in patients (4189±1202) vs controls (1499±338); cortisol AUC similar (484±80 vs 524±107).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested ACTH release (peak)
result GHRP-6‑induced peak ACTH rose from 60.7 ± 17.2 pmol/L pre‑treatment to 78.5 ± 12.1 pmol/L after 6 months ketoconazole (p ns).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested serum cortisol peak after GHRP-6
result Mean cortisol peak 227±25.7 nmol/l in AI vs 395±35.3 nmol/l in AS; ROC threshold 299 nmol/l (Sens 71.0%, Spec 77.8%).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested GH, ACTH, cortisol release
result GH peak after GHRP‑6: 13.8 ± 2.3 µg/L (hyperthyroid) vs 25.4 ± 2.7 µg/L (controls); after 6 mo euthyroidism 15.6 ± 3.6 µg/L
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested plasma GHRP-6 concentration
result LOQ 5 ng/mL, calibration range 5–50 ng/mL, R² > 0.988; method applied to plasma of 9 healthy volunteers in a phase I trial.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested distribution half-life 7.6 ± 1.9 min; elimination half-life 2.5 ± 1.1 h; AUC increased proportionally with dose; occasional concentration spikes observed
result distribution half-life 7.6 ± 1.9 min; elimination half-life 2.5 ± 1.1 h; AUC increased proportionally with dose
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested growth hormone secretion (delta GH)
result GHRH alone gave blunted GH response in glucocorticoid patients (median ΔGH 0.9 µg/L) vs normals (7.1 µg/L); hexarelin restored response (median ΔGH 15.5 µg/L) comparable to normals (17.9 µg/L)
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested GH secretion (peak and AUC) and IGF‑I levels
result Oral GHRP-6 (300 µg/kg) raised GH peak to 10.7 ± 3.3 µg/L (AUC 353.1 ± 90.6) vs IV GHRH 5.1 ± 1.5 µg/L; after 4 days GH peak 16.8 ± 2.9 µg/L (AUC 499.8 ± 107.2); IGF‑I unchanged (77.1 → 84.1 µg/L, ns).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested GH peak response
result Peak GH responses to GHRP and GHRH were not correlated (r=0.57, P=0.066); peak GH responses to GHRP and TRH were highly correlated (r=0.95, P<0.001).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested growth hormone peak amplitude and frequency
result GHRP-6 induced long‑lasting peaks with high amplitude; GHRP-6 plus exercise further increased the amplitude of GH peaks.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Preclinical / mechanistic research
tested rat · An electrophysiological and morphological investigation of the projections of growth hormone-releasing peptide-6-responsive neurons in the rat arcuate nucleus to the median eminence and to the paraventricular nucleus. (PMID 10218787 · DOI 10.1016/s0306-4522(98)00532-6)
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Gastric motor effects of ghrelin and growth hormone releasing peptide 6 in diabetic mice with gastroparesis.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rodent · Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Ghrelin-attenuated cognitive dysfunction in streptozotocin-induced diabetic rats.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Differential effects of ghrelin antagonists on alcohol drinking and reinforcement in mouse and rat models of alcohol dependence.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Ghrelin-Induced Enhancement of Vasopressin and Oxytocin Secretion in Rat Neurohypophyseal Cell Cultures.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Atheroprotective and atheroregressive potential of azapeptide derivatives of GHRP-6 as selective CD36 ligands in apolipoprotein E-deficient mice.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Ghrelin improves cognition via activation of the cAMP- CREB signalling pathway in depressed male C57BL/6J mice.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Antagonism of the ghrelin receptor type 1a in the rat brain induces status epilepticus in an electrical kindling model of epilepsy.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Ghrelin misbalance affects mice embryo implantation and pregnancy success by uterine immune dysregulation and nitrosative stress.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Changes in Locomotor Activity Observed During Acute Nicotine Withdrawal Can Be Attenuated by Ghrelin and GHRP-6 in Rats.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · A novel butyrylcholinesterase inhibitor induces antidepressant, pro-cognitive, and anti-anhedonic effects in Flinders Sensitive Line rats: The role of the ghrelin-dopamine cascade.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested In vitro release study of mono-PEGylated growth hormone-releasing peptide-6 from PLGA microspheres.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Therapeutic effects of ghrelin and growth hormone releasing peptide 6 on gastroparesis in streptozotocin-induced diabetic guinea pigs in vivo and in vitro.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Ghrelin antagonist D-Lys3-GHRP-6 counteract ghrelin effects in bovine cumulus-oocytes complexes matured in vitro.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Ghrelin Improves Glucolipotoxicity-Induced Pancreatic β-Cellular Dysfunction and Apoptosis by Inhibiting Endoplasmic Reticulum Stress-Induced IRE1/JNK Pathway.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Assessing The Effectiveness of Growth Hormone Releasing Protein-6 in Improving Human Oocyte Maturation and Meiotic Progression in <i>In Vitro</i> Maturation Culture Media.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.